Pharmafile Logo
Pharmafocus logo
Advanced Search

deal

Showing 15 posts of 34 posts found.

allergan

Allergan acquires neurotoxin specialist Bonti in $195m deal

September 17, 2018
Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal

The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 …

News

Novartis buys eczema drug in €95m deal

July 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent

Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …

News
489px-trump_executive_michael_cohen_013_cropped

Senate claims Novartis misled public on Trump lawyer deal

July 16, 2018
Sales and Marketing Novartis, Senate, Trump, United States, deal

A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen …

News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016
Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …

News

Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal

July 6, 2016
Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer

Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …

News
novartis_outside_1

Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …

News
shire_image_4

Shire completes Baxalta takeover

June 3, 2016
Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT).  The …

News

Monsanto rejects Bayer’s $62 billion offer

May 25, 2016
Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto

World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …

News

Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal

May 19, 2016
Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results

Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …

News
biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016
Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …

News
sanofi_pasteur_scientist

Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition

May 13, 2016
Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal

French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …

News

Sanofi makes unsolicited $9.8 billion bid for Medivation

April 28, 2016
Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer

French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …

News
regeneron

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …

News
pfizer_logo

Pfizer to call off $160 billion merger with Allergan

April 6, 2016
Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …

News

AstraZeneca completes respiratory deal with Almirall

November 3, 2014
Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory

AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026